1
Dale B Schenk, Peter A Seubert, Carmen Vigo Pelfrey: Methods for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, January 14, 1997: US05593846 (182 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


2
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods for monitoring cellular processing of .beta.-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, August 15, 1995: US05441870 (130 worldwide citation)

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


3
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP. Athena Neurosciences, Eli Lilly and Company, John Storella, Jean Duvall, February 24, 1998: US05721130 (93 worldwide citation)

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


4
Peter A Seubert, Carmen Vigo Pelfrey, Dale B Schenk, Robin Barbour: Methods for aiding in the diagnosis of Alzheimers disease by measuring amyloid-.beta. peptide (x-.gtoreq.41). Elan Pharmaceuticals, Eli Lilly & Company, Carol A Stratford, Jean M Duvall, September 5, 2000: US06114133 (87 worldwide citation)

This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. ...


5
Dale B Schenk, Michael G Schlossmacher, Dennis J Selkoe, Peter A Seubert, Carmen Vigo Pelfrey: Methods and compositions for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Brigham and Women s Hospital, Townsend and Townsend and Crew, November 17, 1998: US05837672 (81 worldwide citation)

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


6
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Jean M Duvall, John R Storella, February 25, 1997: US05605811 (74 worldwide citation)

The present invention provides methods for identifying beta amyloid production inhibitors, wherein cells are cultured under conditions which result in secretion of a soluble fragment of beta amyloid precursor protein. The amino acid sequence of the fragment extends from the amino terminus of beta AP ...


7
Lisa C McConlogue, Dale B Schenk, Peter A Seubert, Sukanto Sinha, Jun Zhao: Methods of screening for .beta.-amyloid peptide production inhibitors. Athena Neurosciences, Townsend and Townsend and Crew, February 18, 1997: US05604102 (72 worldwide citation)

Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble amino-terminal fragment or .beta.APP (ATF-.beta.APP) resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. Secretion of ATF-.beta.APP in animal models may b ...


8

9
Martin Citron, Dennis J Selkoe, Peter A Seubert, Dale Schenk: Screening compounds for the ability to alter the production of amyloid-&bgr; peptide. Brigham and Women&apos s Hospital, Athena Neurosciences, Townsend and Townsend and Crew, August 26, 2003: US06610493 (43 worldwide citation)

This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x≧41) alone or in combination with A&bgr;(x≦40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x≦40) and A&bgr;(x≧41) produced b ...


10
Harry F Dovey, Peter A Seubert, Sukanto Sinha: Amyloidin protease and uses thereof. Athena Neurosciences, Eli Lilly and Company, Jean M Duvall, June 13, 1995: US05424205 (26 worldwide citation)

A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid p ...